Metabolic indicators that may correlate with reduced GLP-1 activity include: Persistent hyperglycemia despite dietary modifications, particularly elevated postprandial (after-meal) blood glucose levels Difficulty achieving satiety after meals, leading to continued hunger and frequent snacking Progressive weight gain that is resistant to conventional dietary interventions Diagnosis of prediabetes or type 2 diabetes , conditions associated with impaired incretin response Metabolic syndrome features , including central obesity, hypertension, and dyslipidemia It is important to emphasize that these signs are not diagnostic of GLP-1 imbalance specifically, as they can result from numerous metabolic, endocrine, or lifestyle factors
Many insurance plans do not cover weight loss medications, such as semaglutide and tirzepatide
Complicated unstable cardiovascular disease, severe kidney disease, history of recurrent pancreatitis, gastroparesis, or multiple complex medication regimens may need more intensive medical supervision than telehealth provides
Your appetite suppression from semaglutide means you'll likely need fewer total calories anywayfocus on quality over quantity, and listen to hunger cues rather than forcing shakes if you're not genuinely hungry
USD 39.95 Prices may be subject to local taxes which are calculated during checkout Similar content being viewed by others References Abbafati C, Abbas KM, Abbasi-Kangevari M, Abd-Allah F, Abdelalim A, Abdollahi M, et al
Natural weight loss or Ozempic face: Demystifying a social media phenomenon